ERBA Mannheim Launches CE Marked COVID-19 Antibody ELISA Kits

Erba Mannheim (London, England) has launched its ErbaLisa COVID-19 ELISA kits for detection of IgG and IgM antibodies to SARS-CoV-2. The assays have been designed for use either manually or with any open automated ELISA analyzer, such as the Erba Mannheim ELAN 30s.

SARS-CoV-2 viral antigens stimulate the body's immune system to produce antibodies that can be detected with IgM and IgG antibody tests. IgM is produced first and is detectable during early onset of the disease. IgG is produced later and is maintained for long-term immunity. The ready-to-use ErbaLisa COVID-19 ELISA kits will allow not only qualitative, but also semi-quantitative detection of the IgG and IgM antibodies. Erba Mannheim has filed applications for both assays with the FDA's Emergency Use Notification process, and CE certification has already been granted. The kits are available through the company’s global distribution network, including in the US.

“Our IgM test could be used to identify people recently infected by the virus, including those who may not have displayed symptoms,” said Petros Sarantos, Global Product Manager for Immunoassay. “The IgG test will provide an accurate measure of how many people have been infected and may have developed immunity. Once identified, immune individuals could safely return to work and help relieve stressed healthcare systems or other frontline functions. Such people could also donate their blood to potentially save other patients with severe COVID-19.”

"We are very proud to be contributing towards the fight against COVID-19. Having a better understanding about the immunity of COVID-19 will help society move back towards normality," said Nikhil Vazirani, MD of Erba Mannheim.